Cosmo (SIX: COPN, XETRA: C43) is a pharmaceutical company focused on developing and manufacturing innovative products in the fields of gastroenterology, healthtech and dermatology. The 6 drug products and 3 medical devices which Cosmo has developed are all approved and distributed globally by its selected partners.
Lialda®/ Mezavant®/Mesavancol® and Uceris®/Cortiment®, for the treatment of ulcerative colitis; Aemcolo®, antibiotic for the treatment of travellers’ diarrhoea; Lumeblue® for the visualisation of colorectal lesions during colonoscopy; Byfavo®, a novel sedative for procedural sedation; and more recently Winlevi® for the treatment of acne which is distributed by Sun Pharma in the US and Canada.
Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™, which uses Artificial Intelligence to aid the detection of colorectal polyps during colonoscopy to help detect potential signs of colon cancer and Eleview®, a submucosal injectable composition for use in gastrointestinal endoscopic procedures.
The Company’s extensive galenic experience, which led to the development of the proprietary multi-matrix technology MMX®, provides an excellent basis for the development of new, patentable, yet lower-risk products, manufactured at the Company’s own and GMP–approved plant. Cosmo has a demonstrated ability to successfully identify unmet medical needs, manage the drug development process and obtain regulatory approval for new products. Cosmo then licenses its approved products to partners with strong marketing and sales expertise.
Cosmo’s therapeutic focus is on the oral and endoscopic treatment of colon diseases, primarily bowel diseases and colorectal cancer prevention. It’s MMX® technology allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets, in a delayed and controlled way, with the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.